Close

Myriad Genetics (MYGN), AstraZeneca (AZN) Expand Lynparza Development Collaboration

April 1, 2015 7:15 AM EDT Send to a Friend
Myriad Genetics (NASDAQ: MYGN) announced the expansion of its companion diagnostic collaboration with AstraZeneca (NYSE: AZN). Under the terms of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login